USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration. It offers Celavive, a skincare regimen for various skin care types and ethnicities; and all other products comprising materials and online tools for associates to build business and marketing of products The company sells its products through retail customers, a subscription model, and direct selling, as well as online. The company was founded in 1992 and is headquartered in Salt Lake City, Utah.…
USANA Health Sciences Q3 Earnings Call Highlights
USANA Health Sciences (NYSE: USNA) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Packaged Foods industry, part of the Consumer Defensive sector, and reports about 1,570 employees.
The shares were at 12.94 USD on 20 November 2026, down 31.6% over 52 weeks. Its 52-week range is 12.53 USD to 23.59 USD: the price is 45.1% below the high and 3.3% above the low.
Its market capitalisation is 239.24M USD.
USANA Health Sciences reports return on equity of 2.0%, an operating margin of 4.3% and revenue down 3.6% year over year.
It holds more cash than debt, a net cash position of 178.92M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. One analyst covers the stock; their mean price target of 22.00 USD is 70.0% above the current price. The next earnings report is expected on 16 February 2027.